What Does Divalproex Treat? Seizures, Bipolar & More

Divalproex sodium has three FDA-approved uses: treating epileptic seizures, managing manic and mixed episodes in bipolar disorder, and preventing migraines. Beyond those approved indications, it gets prescribed off-label for a handful of other conditions with varying levels of evidence. The drug is essentially a stable combination of valproic acid and sodium valproate, and once it dissolves in the gut it delivers the same active compound, valproate, that neurologists and psychiatrists have relied on since the late 1960s. But its reach across such different conditions raises a fair question: how does one medication work for problems as unrelated as seizures and headaches?

Seizures and Epilepsy

Seizure control was the original reason divalproex was developed, and it remains one of the drug’s strongest evidence bases. Valproic acid’s anticonvulsant properties were discovered in 1967, and divalproex sodium became available in the United States for epilepsy in 1983.¹ The drug works against a broad range of seizure types, which is part of what made it so popular so quickly. Many anticonvulsants are effective only against certain seizure patterns; divalproex handles both generalized seizures (the kind that affect the whole brain at once) and partial seizures (those starting in one region).

Clinical trials from the 1990s established the numbers prescribers still rely on. In a double-blind study of patients with complex partial seizures, those who reached higher blood levels of valproate saw a 30% median reduction in complex partial seizures and a 70% median reduction in secondarily generalized tonic-clonic seizures, compared with increases in the group kept at lower levels.² When used as an add-on therapy for people whose seizures weren’t controlled by other medications, about 38% of divalproex-treated patients achieved at least a 50% drop in complex partial seizures, compared with 19% on placebo.³ Those results were strong enough to secure divalproex’s position as a first-line epilepsy treatment, a status it still holds for certain seizure types.

For absence seizures, which are brief staring spells most common in children, divalproex is often considered the drug of choice. It also has good evidence in myoclonic epilepsy and in juvenile myoclonic epilepsy specifically, where the seizure disorder tends to be lifelong and requires reliable long-term medication. Newer anticonvulsants have since crowded the field, and divalproex has lost some market share to drugs with fewer side effects, but its broad spectrum of activity keeps it relevant for patients who have more than one seizure type or who haven’t responded well to alternatives.

Bipolar Disorder

Divalproex’s second major use came when researchers noticed that its mood-stabilizing effects went beyond what you’d expect from a simple anticonvulsant. It now carries FDA approval specifically for treating manic and mixed episodes in bipolar I disorder.⁴ A manic episode involves abnormally elevated or irritable mood, racing thoughts, decreased sleep, and impulsive behavior. A mixed episode combines features of mania and depression simultaneously, which can be especially destabilizing.

In acute mania, divalproex performs comparably to lithium, the oldest mood stabilizer in the book. A randomized trial in older adults (age 60 and up) with bipolar I found nine-week response rates of 73% for divalproex and 79% for lithium, with no statistically significant difference between them.⁵ Both drugs worked well, though lithium was associated with a somewhat greater reduction in mania scores over the study period.

The maintenance question is trickier. A 12-month placebo-controlled trial of outpatients with bipolar I found that median time to the next mood episode was 40 weeks for divalproex, 24 weeks for lithium, and 28 weeks for placebo. The divalproex-lithium difference approached but didn’t reach statistical significance. Patients on divalproex did stay on treatment significantly longer than those on lithium, which matters in a condition where sticking with medication is one of the biggest practical challenges.⁶ A Cochrane review looking at the available maintenance data concluded there was no significant difference between divalproex and lithium in preventing mood episodes, though some secondary analyses leaned slightly in favor of divalproex.⁷

Rapid-cycling bipolar disorder, where a person has four or more mood episodes in a year, was once thought to respond better to divalproex than lithium. A 20-month head-to-head trial didn’t bear that out: relapse rates were similar (50% for divalproex, 56% for lithium), and neither drug was impressively effective at preventing new episodes. One notable difference was tolerability. Only 4% of divalproex patients dropped out because of side effects, compared with 16% on lithium.⁸ That pattern comes up repeatedly: divalproex and lithium often look similar in efficacy, but divalproex tends to be easier to tolerate, which is a practical advantage when patients need to stay on medication for years.

Migraine Prevention

Divalproex’s third FDA-approved indication is migraine prophylaxis, meaning it’s taken daily to reduce how often migraines occur. It doesn’t stop a migraine once one starts, but for people who get frequent attacks, it can meaningfully thin out the frequency. A randomized trial of the extended-release formulation showed that patients taking divalproex averaged about 1.2 fewer migraines per four-week period (from a baseline of roughly 4.4 per month), compared with a reduction of 0.6 on placebo.⁹

A dose-ranging study found that roughly 44 to 45% of patients on divalproex achieved at least a 50% reduction in migraine attacks, compared with 21% on placebo. Interestingly, higher doses didn’t appear to work better than moderate ones: patients on 500 mg, 1,000 mg, and 1,500 mg daily all showed similar improvements.¹⁰ That’s good news for tolerability, since side effects are generally dose-dependent. There’s also limited evidence suggesting benefit in cluster headache, with about 73% of cluster patients in one study reporting decreased pain on divalproex.¹¹

The migraine field has changed significantly with the arrival of CGRP-targeting medications, which are designed specifically for migraine and tend to have fewer systemic side effects. Divalproex is now used less often as a first-choice preventive, but it remains an option for people who haven’t responded to or can’t access newer therapies, particularly because it’s available as a generic and costs considerably less.

Off-Label Uses

Divalproex is prescribed off-label for a number of conditions where evidence ranges from promising to weak. Two areas have attracted the most formal study: agitation in dementia and aggression in borderline personality disorder.

For dementia-related agitation, the news is largely disappointing. An early small trial hinted at possible short-term benefit, with 68% of divalproex-treated patients rated as showing reduced agitation versus 52% on placebo, though the result didn’t reach statistical significance.¹² But larger and more rigorous studies failed to confirm any meaningful effect. A trial specifically designed to test whether chronic divalproex could slow the progression of agitation in Alzheimer’s disease found no difference from placebo on any behavioral, cognitive, or functional measure.¹³ A Cochrane review synthesizing the available evidence concluded that valproate preparations probably have little or no effect on agitation in dementia.¹⁴ Despite this, divalproex continues to be prescribed off-label in some nursing home settings, a practice that has drawn criticism.

Borderline personality disorder is a different story. A double-blind pilot study in women with borderline personality disorder (many of whom also had bipolar II disorder) found that divalproex was superior to placebo in reducing interpersonal sensitivity, anger, and overall aggression.¹⁵ A follow-up analysis showed that the drug particularly helped patients with higher baseline levels of impulsivity and state aggression, suggesting it works best for a specific symptom profile rather than the disorder broadly.¹⁶ The evidence here is still considered preliminary, and divalproex is far from a standard treatment for borderline personality disorder, but for the specific symptom of impulsive aggression, it’s a reasonable off-label option some psychiatrists reach for.

How Divalproex Differs from Plain Valproic Acid

If divalproex and valproic acid deliver the same active drug once absorbed, why does the distinction matter? Mostly for your stomach. Divalproex sodium is a stable coordination compound that doesn’t fully break apart until it hits the intestine, which means less direct contact between valproic acid and the stomach lining. A pharmacoepidemiology study comparing the two found that gastrointestinal side effects were about half as common with divalproex: roughly 15% of divalproex patients reported GI problems versus 29% on valproic acid. Nausea and vomiting specifically occurred in about 7% of the divalproex group versus 17% on valproic acid. Patients on divalproex were also significantly less likely to stop their medication because of side effects.¹⁷ A separate study in hospitalized patients with psychotic disorders confirmed the same pattern of more grouped GI side effects with valproic acid, though it noted the clinical significance was debatable since discontinuation rates didn’t differ in that particular setting.¹⁸

Divalproex comes in several formulations: a delayed-release tablet (the original Depakote), an extended-release version (Depakote ER), and sprinkle capsules that can be opened and mixed with soft food for people who have trouble swallowing pills. The extended-release version is taken once daily and produces smoother blood levels, which some patients tolerate better. For migraine prophylaxis, most of the recent trial data used the extended-release form.

Serious Safety Concerns

Divalproex carries several boxed warnings, the most serious category of FDA safety alert. Liver toxicity is the best known. Fatal cases of hepatic failure have occurred, most often in children under two years old who are taking multiple anticonvulsants and have underlying metabolic disorders. The risk drops sharply in older patients and in people on divalproex alone, but liver function tests are still routinely checked, especially during the first six months.

Pancreatitis is another rare but potentially life-threatening risk. A systematic review of published cases found that the diagnosis was typically made around 11 months after starting valproic acid, though some cases appeared much earlier. Among reported cases, 84% recovered and 16% died. A troubling finding was that when 19 patients were re-exposed to valproic acid after recovering from pancreatitis, 16 of them (84%) developed another episode.¹⁹ An earlier review noted that the highest risk window appeared to be the first few months of treatment, with about 44% of cases developing within the first three months and 69% within the first year.²⁰ That said, when researchers examined clinical trial databases, the actual incidence was very low: among over 3,000 valproate-treated patients across 34 clinical trials, only two cases of pancreatitis were considered probably drug-related, and both patients recovered.²¹

The third boxed warning concerns pregnancy. Valproate is among the most teratogenic of all commonly used medications, meaning it carries a high risk of birth defects when taken during pregnancy. Neural tube defects, heart malformations, and other structural problems occur at significantly elevated rates. Beyond structural birth defects, children exposed to valproate in the womb also show lower average IQ scores. For this reason, divalproex is generally avoided in women of childbearing potential unless other treatments have failed and effective contraception is in place.

Weight Gain and Hormonal Effects in Women

Weight gain on divalproex is not a minor cosmetic nuisance. In a study of women taking valproate for epilepsy, roughly half gained a substantial amount of weight, with a mean gain of about 21 kg (46 pounds) and a range extending up to 49 kg (108 pounds). Fifty-nine percent of the women on valproate were classified as obese.²² The weight gain appears to be driven at least partly by increased insulin levels, and it tends to be progressive rather than leveling off after the first few months.

The hormonal picture is intertwined with the weight issue. That same study found that 64% of women on valproate had polycystic ovaries, elevated androgen levels, or both. Case reports have documented women developing the full picture of polycystic ovary syndrome (PCOS) while on valproate, with the condition resolving after switching to a different medication.²³ Among women treated with valproate for bipolar disorder, about 38% reported developing menstrual abnormalities after starting the medication.²⁴ Whether valproate actually causes PCOS or simply pushes susceptible women over a threshold is still debated, but the clinical implication is clear: women starting divalproex should be aware that menstrual changes, weight gain, and hormonal shifts are realistic possibilities that warrant monitoring.

Hyperammonemia and Blood Effects

One of the more underappreciated side effects of valproate is elevated ammonia in the blood. This can happen even when blood levels of the drug itself are perfectly normal and liver function tests look fine.²⁵ In mild cases, the person might not notice anything. In more severe cases, rising ammonia can cause confusion, excessive sleepiness, decreased responsiveness, and what’s formally called hyperammonemic encephalopathy. A case report described an elderly woman whose ammonia rose to dangerous levels despite a normal valproate concentration, along with a simultaneous drop in platelet count. Both problems resolved after the drug was stopped.²⁶

Thrombocytopenia (low platelet count) is common enough with valproate that periodic blood counts are part of standard monitoring. The effect is generally dose-dependent, and most patients don’t develop clinically significant bleeding problems. But for people on blood thinners or facing surgery, a valproate-related platelet dip can complicate things. Tremor is another neurological side effect that some patients find bothersome, and it too tends to worsen at higher doses.

Drug Interactions Worth Knowing About

Divalproex has a clinically important interaction with lamotrigine, another medication widely used for both epilepsy and bipolar disorder. Valproate inhibits the body’s clearance of lamotrigine, roughly doubling its blood levels. This matters because lamotrigine at elevated levels can cause serious skin reactions. When someone is taking both drugs, the lamotrigine dose typically needs to be cut in half. If valproate is later discontinued, the inhibition reverses over about 10 to 14 days, meaning lamotrigine levels will gradually rise back toward what they’d be without the interaction.²⁷ Even very low concentrations of valproate can affect lamotrigine clearance, so the interaction doesn’t simply disappear with a dose reduction.²⁸

Valproate also interacts with other anticonvulsants. Carbamazepine and phenytoin can lower valproate levels by speeding up its metabolism, potentially reducing its effectiveness. Conversely, valproate can raise levels of certain drugs by competing for the same metabolic pathways. Aspirin at high doses can displace valproate from protein binding, increasing the free (active) fraction of the drug in the blood. For anyone taking divalproex, a careful medication review is essential whenever a new drug is added or an existing one is stopped.

Monitoring and Blood Levels

Divalproex is one of the drugs where blood level monitoring is standard practice. The generally accepted therapeutic range for total valproate is roughly 50 to 100 micrograms per milliliter for epilepsy and bipolar disorder, though individual patients may do well at different levels. A study examining the relationship between total and free valproate concentrations found that the free fraction (the portion actually active in the body) stays stable at around 10% when total levels are between 20 and 60 micrograms per milliliter, but starts rising disproportionately above that threshold.²⁹ That means pushing doses higher requires more caution, since side effects track with the free fraction, not just the total level.

Beyond drug levels, routine monitoring typically includes liver function tests (especially in the first six months), a complete blood count to watch for platelet changes, and ammonia levels if confusion or unexplained drowsiness develops. For women of reproductive age, tracking weight, menstrual patterns, and potentially hormonal levels adds another layer. All of this monitoring makes divalproex a higher-maintenance medication compared to some newer alternatives, but for patients who respond well to it, the benefits can justify the bookkeeping.

Why One Drug Works on So Many Conditions

It might seem strange that the same pill can treat seizures, stabilize mood, and prevent headaches. The explanation is that valproate doesn’t do just one thing biochemically. It enhances the activity of GABA, the brain’s main inhibitory chemical messenger, which dampens excessive neural firing. That mechanism is most directly relevant to seizure control but also plays a role in mood regulation. The drug also modulates sodium and calcium channels in neurons, further quieting overexcitable circuits.

More recently, researchers discovered that valproic acid inhibits histone deacetylases (HDACs), enzymes involved in controlling which genes get turned on or off.³⁰ This epigenetic activity has opened up research into whether valproate might have applications in cancer and neurodegenerative disease.³¹ Those applications remain experimental, and valproate’s side effect profile would be a major obstacle to repurposing it for conditions where safer alternatives exist. But the HDAC discovery helps explain why a drug first used as a simple anticonvulsant keeps showing up in such varied clinical contexts. It was originally an organic solvent used in laboratories for decades before anyone realized it had biological activity at all.³² Each new mechanism that researchers uncover has suggested yet another potential application, a pattern that has kept this old drug surprisingly relevant in a field full of newer, more targeted therapies.